A recent clinical trial has demonstrated that the drug, IONIS-HTTRx, is safe for use in people with Huntington’s disease.
Researchers have revealed that reducing mutant huntingtin protein in the brain could restore cognitive and psychiatric impairments in mice.
Lausanne University Hospital (Switzerland) researchers reveal the promise of genome editing for the treatment of Huntington’s disease.
Ionis Pharmaceuticals recently announced their results from the IONIS-HTT Rx (RG6042) Phase I/II trial, reporting it to be the first drug in development to reduce disease-causing mutant huntingtin protein in people with Huntington’s disease.
New research suggests Huntington’s disease may provide protection from cancer.
For the first time, a treatment has been found to halt progression of Huntington’s disease by lowering levels of mutant huntingtin protein in the nervous system.
An international research team have shown that gene editing reverses Huntington’s symptoms without off-target effects in a mouse model.
Researchers have developed computer models to further understanding the behavior of protein fragments and fibril aggregation in Huntington’s disease development.
Oliver Quarrell, Consultant Clinical Geneticist and expert in Huntington’s disease (HD), discusses global prevalence of the disease and his projections for the future of HD research.
Researchers have engineered a zinc finger protein that is able reduce activity of the huntingtin gene for six months in mice.